| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
OXFORD, U.K.—In a single day, biotech company VASTox made major moves to expand its capabilities, announcing the acquisition of Cambridge, UK-based DanioLabs and Reading, UK-based Dextra Laboratories. The deals see the company expand its pipeline with two clinical and two preclinical programs, as well as expanding it R&D capabilities in the areas of chemical genomics using zebrafish and sugar chemistry.
 
DanioLabs was acquired for £15 million in shares and cash, with VASTox retaining its research facility and maintaining its 37 personnel. Meanwhile, Dextra had a lower price tag of £1.5 million, also paid in shares, and as with the other deal, VASTox will retain the chemistry facility and all 17 employees.
 
"The acquisitions of DanioLabs and Dextra represent a transforming development for VASTox," said VASTox CEO Dr. Steve Lee. "Following these transactions, plus the earlier deal with MNL Pharma in December 2006, VASTox now has a broad drug discovery pipeline with programs in clinical and discovery phases of development targeting neuro-disorders, cancer, ophthalmology, infectious diseases and regenerative medicine."

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue